XOMA Stock Analysis: XOMA Royalty | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 775m USD | 12M Return: 67.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.64M
Qual. Beats: 0
Rev. Trend: 94.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
XOMA Royalty Corporation is a U.S.-based biotech royalty aggregator that acquires economic rights to future milestone and royalty payments from therapeutic candidates and commercial products. The company operates across the United States, Switzerland, the Asia Pacific, and Australia, and maintains a diversified portfolio spanning pre-commercial assets (primarily Phase 1 and 2 clinical candidates licensed to third-party sponsors) as well as late-stage and commercial-stage milestone and royalty streams.
The company was incorporated in 1981 and is headquartered in Emeryville, California. It was originally known as XOMA Corporation before rebranding to XOMA Royalty Corporation in July 2024, reflecting its strategic shift toward a royalty aggregation business model. As a royalty aggregator, XOMA provides non-dilutive financing to drug developers in exchange for future payments tied to regulatory and commercial milestones, generating revenue without directly conducting drug discovery or commercialization itself. The company trades on NASDAQ under the ticker XOMA and is classified within the Health Care sector, Biotechnology sub-industry.
- Royalty stream acquisitions accelerate portfolio expansion
- Phase 2 clinical milestones trigger partner payment events
- Partnered product sales growth boosts recurring royalty income
| Net Income: 31.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 5.58 > 1.0 |
| NWC/Revenue: 236.5% < 20% (prev 247.6%; Δ -11.13% < -1%) |
| CFO/TA 0.02 > 3% & CFO 6.63m > Net Income 31.5m |
| Net Debt (51.7m) to EBITDA (50.2m): 1.03 < 3 |
| Current Ratio: 3.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.4m) vs 12m ago 18.23% < -2% |
| Gross Margin: 90.86% > 18% (prev 94.06%; Δ -3.20% > 0.5%) |
| Asset Turnover: 14.95% > 50% (prev 17.62%; Δ -2.66% > 0%) |
| Interest Coverage Ratio: 3.62 > 6 (EBIT TTM 46.8m / Interest Expense TTM 12.9m) |
| A: 0.32 (Total Current Assets 118.7m - Total Current Liabilities 33.1m) / Total Assets 271.9m |
| B: -4.48 (Retained Earnings -1.22b / Total Assets 271.9m) |
| C: 0.19 (EBIT TTM 46.8m / Avg Total Assets 242.3m) |
| D: 0.71 (Book Value of Equity 112.9m / Total Liabilities 159.0m) |
| Altman-Z'' = -10.48 = D |
| DSRI: 1.33 (Receivables 23.3m/18.2m, Revenue 36.2m/37.5m) |
| GMI: 1.04 (GM 94.06% / 90.86%) |
| AQI: 1.21 (AQ_t 0.56 / AQ_t-1 0.47) |
| SGI: 0.97 (Revenue 36.2m / 37.5m) |
| TATA: 0.09 (NI 31.5m - CFO 6.63m) / TA 271.9m) |
| Beneish M = -2.62 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 43.89 with a total of 144,744 shares traded. Over the past week, the price has changed by +4.13%, over one month by +4.70%, over three months by +26.92% and over the past year by +67.71%.
Current recommended Stop Loss: 43.20 (which is 1.6% or 1.3 ATR below the current price).
XOMA Royalty has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy XOMA.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 39 | -11.1% |
P/E Trailing = 27.9299
P/E Forward = 20.8768
P/S = 15.9657
P/B = 6.7334
P/EG = -0.42
Revenue TTM = 36.2m USD
EBIT TTM = 46.8m USD
EBITDA TTM = 50.2m USD
Long Term Debt = 88.8m USD (from longTermDebt, last quarter)
Short Term Debt = 16.4m USD (from shortTermDebt, last quarter)
Debt = 146.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 21.9m
Net Debt = 51.7m USD (calculated: Debt 146.6m - CCE 95.0m)
Enterprise Value = 826.9m USD (775.2m + Debt 146.6m - CCE 95.0m)
Interest Coverage Ratio = 3.62 (Ebit TTM 46.8m / Interest Expense TTM 12.9m)
EV/FCF = 124.6x (Enterprise Value 826.9m / FCF TTM 6.63m)
FCF Yield = 0.80% (FCF TTM 6.63m / Enterprise Value 826.9m)
FCF Margin = 18.31% (FCF TTM 6.63m / Revenue TTM 36.2m)
Net Margin = 86.97% (Net Income TTM 31.5m / Revenue TTM 36.2m)
Gross Margin = 90.86% ((Revenue TTM 36.2m - Cost of Revenue TTM 3.31m) / Revenue TTM)
Gross Margin QoQ = 92.76% (prev 38.27%)
Tobins Q-Ratio = 3.04 (Enterprise Value 826.9m / Total Assets 271.9m)
Interest Expense / Debt = 8.81% (Interest Expense 12.9m / Debt 146.6m)
Taxrate = 0.02% (1.00k / 4.47m)
NOPAT = 46.8m (EBIT 46.8m * (1 - 0.02%))
Current Ratio = 3.59 (Total Current Assets 118.7m / Total Current Liabilities 33.1m)
Debt / Equity = 1.30 (Debt 146.6m / totalStockholderEquity, last quarter 112.9m)
Debt / EBITDA = 1.03 (Net Debt 51.7m / EBITDA 50.2m)
Debt / FCF = 7.79 (Net Debt 51.7m / FCF TTM 6.63m)
Total Stockholder Equity = 104.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.00% (Net Income 31.5m / Total Assets 271.9m)
RoE = 30.21% (Net Income TTM 31.5m / Total Stockholder Equity 104.3m)
RoCE = 24.25% (EBIT 46.8m / Capital Employed (Equity 104.3m + L.T.Debt 88.8m))
RoIC = 18.48% (NOPAT 46.8m / Invested Capital 253.4m)
WACC = 10.17% (E(775.2m)/V(921.8m) * Re(10.43%) + D(146.6m)/V(921.8m) * Rd(8.81%) * (1-Tc(0.00)))
Discount Rate = 10.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 20.37%
[DCF] Terminal Value 69.32% ; FCFF base≈6.63m ; Y1≈6.66m ; Y5≈7.06m
[DCF] Fair Price = 1.82 (EV 83.8m - Net Debt 51.7m = Equity 32.1m / Shares 17.7m; r=10.17% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.33 | # QB: 0
Revenue Correlation: 94.58 | Revenue CAGR: 183.9% | SUE: -0.43 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.17 | Chg30d=-23.08% | Revisions=-25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.26 | Chg30d=-32.03% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.79 | Chg30d=-28.61% | Revisions=+17% | GrowthEPS=-46.1% | GrowthRev=+16.5%
EPS next Year (2027-12-31): EPS=-0.05 | Chg30d=-107.30% | Revisions=+0% | GrowthEPS=-106.4% | GrowthRev=-13.6%
[Analyst] Revisions Ratio: -10% (up=3, down=4)